Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.

ABSTRACT:

Background

Among men with metastatic prostate cancer, about 10% have germline alterations in DNA damage response genes. Most studies have examined BRCA2 alone or an aggregate of BRCA1/2 and ATM. Emerging data suggest that ATM mutations may have distinct biology and warrant individual evaluation. The objective of this study is to determine whether response to prostate cancer systemic therapies differs between men with germline mutations in ATM (gATM) and BRCA2 (gBRCA2).

Methods

This is an international multicenter retrospective matched cohort study of men with prostate cancer harboring gATM or gBRCA2. PSA₅₀ response (≥50% decline in prostate-specific antigen) was compared using Fisher's exact test.

Results and limitations

The study included 45 gATM and 45 gB

SUBMITTER: Sokolova AO 

PROVIDER: S-EPMC8563438 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature